Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis

Tanezumab is a new therapeutic intervention for patients with osteoarthritis (OA) of the knee. We performed the present meta-analysis to appraise the efficacy and safety of tanezumab for patients with knee OA. We systematically searched randomized controlled trials from PubMed, EMBASE, and the Cochr...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-06, Vol.11 (6), p.e0157105
Main Authors: Kan, Shun-Li, Li, Yan, Ning, Guang-Zhi, Yuan, Zhi-Fang, Chen, Ling-Xiao, Bi, Ming-Chao, Sun, Jing-Cheng, Feng, Shi-Qing
Format: Article
Language:English
Subjects:
Analgesics
Analysis
Antibodies, Monoclonal, Humanized - therapeutic use
Arthritis
Biocompatibility
Biology and Life Sciences
Care and treatment
Clinical trials
Complications and side effects
Confidence intervals
Critical care
Dose-Response Relationship, Drug
Drugs
Growth factors
Health aspects
Hospitals
Humans
Intervention
Knee
Medicine and Health Sciences
Meta-analysis
Nonsteroidal anti-inflammatory agents
Older people
Osteoarthritis
Osteoarthritis, Knee - drug therapy
Osteoarthritis, Knee - epidemiology
Pain
Pain Measurement
Patients
Peripheral neuropathy
Physical Sciences
Quality of life
Randomization
Research and Analysis Methods
Rheumatic diseases
Rheumatism
Safety
Severity of Illness Index
Studies
Surgeons
Systematic review
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tanezumab is a new therapeutic intervention for patients with osteoarthritis (OA) of the knee. We performed the present meta-analysis to appraise the efficacy and safety of tanezumab for patients with knee OA. We systematically searched randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The primary outcomes were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, the WOMAC physical function and patient's global assessment (PGA). Outcomes were reported as the standard mean difference (SMD) or relative risk (RR) with 95% confidence interval (CI). We assessed the pooled data using a random-effects model. Of the identified studies, four were eligible and were included in this meta-analysis (N = 1839 participants). Compared with the placebo groups, tanezumab yielded a significant reduction in mean change in the WOMAC pain (SMD = 0.51, 95% CI 0.34 to 0.69, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0157105